Quantcast

Latest Psoriasis Stories

2014-06-11 16:27:22

Phase 3 Program Underway to Further Assess Brodalumab as Potential Treatment for People Living With Psoriatic Arthritis THOUSAND OAKS, Calif. and LONDON, June 11, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM). These data will also be presented at the 2014 European League Against Rheumatism (EULAR)...

2014-06-11 04:21:56

- Findings Show Positive Association Between Adherence and Anti-TNF Therapy Compared to Conventional Therapy PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were...

2014-06-09 08:28:15

- Glaucoma Phase II ongoing study will enroll patients to the next higher dose without an interim analysis, no safety issues have been recorded PETACH TIKVA, Israel, June 9, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary, OphthaliX, Inc., has issued an update on its clinical developments and strategic...

2014-06-05 23:12:01

ResearchMoz.us includes new market research report "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports. Albany,New York (PRWEB) June 05, 2014 Researchmoz presents this most up-to-date research on "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation". The report focuses primarily on quantitative market metrics in order to characterize the growth and...

2014-06-01 23:01:09

LifeScienceIndustryResearch.com adds Latest Report on “Frontier Pharma: Psoriasis – Identifying and Commercializing First-in-Class Innovation” to its store. Dallas, TX (PRWEB) June 01, 2014 Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly...

2014-05-31 23:09:44

ResearchMoz.us includes new market research report "Frontier Pharma - Psoriasis - Identifying and Commercializing First-in-Class Innovation: Industry Size, Shares, Growth, Analysis, Trends And Forecast" to its huge collection of research reports. Albany, NY (PRWEB) May 31, 2014 Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected...

2014-05-20 12:28:25

LONDON, May 20, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Dermatological Drugs Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/therapeutic/global_dermatological_drugs_market_2014_2018.html TechNavio's analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide....

2014-05-13 15:45:49

Walter & Eliza Hall Institute of Medical Research A team of Melbourne researchers has shown a recently discovered type of cell death called necroptosis could be the underlying cause of inflammatory disease. The research team discovered that a previously identified molecule involved in necroptosis, called RIPK1, was essential for survival by preventing uncontrolled inflammation. This finding could lead to future treatments for inflammatory diseases including Crohn’s disease,...

2014-05-13 08:31:25

Consensus Statement Supports Adoption of Psoriasis Resolution by the World Health Organization (WHO) at Upcoming 67th World Health Assembly PORTLAND, Ore., May 13, 2014 /PRNewswire-USNewswire/ -- The International Federation of Psoriasis Associations (IFPA), European Federation of Psoriasis Associations (EUROPSO), National Psoriasis Foundation (NPF) and The Arthritis Society today issued a joint consensus statement to provide a framework addressing the unmet needs faced by the over 125...

2014-05-13 08:31:13

NEW YORK, May 13, 2014 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) is a development stage biopharmaceutical company that is primarily engaged in developing oncology and dermatology therapies through its two predominant drug candidates, PV-10 and PH-10. The company is working to develop PV-10 for the treatment of several life-threatening cancers, including metastatic melanoma, liver cancer (also known as Hepatocellular carcinoma, or HCC), and breast cancer....


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related